Evidence map›Paper›PMID 33398170›Full record

ArticleNature chemical biology2021

Molecular basis for ubiquitin ligase CRL2

Xiaojie Yan, Xiaolu Wang, Yao Li, Mengqi Zhou, Yanjun Li, Lili Song, Wenyi Mi, Jinrong Min, Cheng Dong

Abstract read
PubMed Publisher
In one paragraph

Article in Nature chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Degrons: defining the rules of protein degradation.Nature reviews. Molecular cell biology · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Molecular basis for C-degron recognition by CRL2Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Xiaojie Yan *Department of Biochemistry and Molecular Biology, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Xiaolu Wang *Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Yao LiDepartment of Biochemistry and Molecular Biology, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Mengqi ZhouStructural Genomics Consortium and Department of Physiology, University of Toronto, Toronto, Ontario, Canada.
Yanjun LiStructural Genomics Consortium and Department of Physiology, University of Toronto, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-9512-5265
Lili SongDepartment of Immunology, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Diseases and Microenvironment of Ministry of Education of China, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Wenyi MiDepartment of Immunology, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Diseases and Microenvironment of Ministry of Education of China, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China. wenyi.mi@tmu.edu.cn.ORCID http://orcid.org/0000-0002-7453-051X
Jinrong MinStructural Genomics Consortium and Department of Physiology, University of Toronto, Toronto, Ontario, Canada. jr.min@utoronto.ca.ORCID http://orcid.org/0000-0001-5210-3130
Cheng DongDepartment of Biochemistry and Molecular Biology, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China. dongcheng@tmu.edu.cn.ORCID http://orcid.org/0000-0002-2891-8759
Tianjin Medical University · CNUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteome integrity depends on the ubiquitin-proteasome system to degrade unwanted or abnormal proteins. In addition to the N-degrons, C-terminal residues of proteins can also serve as degradation signals (C-degrons) that are recognized by specific cullin-RING ubiquitin ligases (CRLs) for proteasomal degradation. FEM1C is a CRL2 substrate receptor that targets the C-terminal arginine degron (Arg/C-degron), but the molecular mechanism of substrate recognition remains largely elusive. Here, we present crystal structures of FEM1C in complex with Arg/C-degron and show that FEM1C utilizes a semi-open binding pocket to capture the C-terminal arginine and that the extreme C-terminal arginine is the major structural determinant in recognition by FEM1C. Together with biochemical and mutagenesis studies, we provide a framework for understanding molecular recognition of the Arg/C-degron by the FEM family of proteins.

Indexed as

Amino Acid SequenceArginineBinding SitesCarrier ProteinsCell Cycle ProteinsCloning, MolecularCrystallography, X-RayEscherichia coliGene ExpressionGenetic VectorsHEK293 CellsHumansModels, MolecularProteasome Endopeptidase ComplexProtein BindingProtein Conformation, alpha-HelicalArginineCarrier ProteinsCell Cycle ProteinsFEM1A protein, humanFEM1B protein, humanFEM1C protein, humanProteasome Endopeptidase ComplexRecombinant ProteinsUbiquitin-Protein Ligase Complexes

Identifiers

PMID33398170
OpenAlexW3120954832

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.